The Risk of Chronic Pancreatitis in Patients with Psoriasis: A Population-Based Cohort Study

Hsien-Yi Chiu1,2,3*, Chi-Feng Hsieh4*, Yi-Ting Chiang4, Weng-Foung Huang4, Tsen-Fang Tsai3*

1 Institute of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University, Taipei, Taiwan, 2 Department of Dermatology, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan, 3 Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan, 4 Institute of Health and Welfare Policy, National Yang-Ming University, Taipei, Taiwan

* These authors contributed equally to this work.
* tftsai@yahoo.com

Abstract

Background
Psoriasis is a chronic systemic inflammatory disorder, and studies have revealed its association with a variety of comorbidities. However, the risk of chronic pancreatitis (CP) in psoriasis has not been studied. This study aimed to investigate the risk of CP among patients with psoriasis.

Methods
Using the Taiwan National Health Insurance Research Database, this population-based cohort study enrolled 48430 patients with psoriasis and 193720 subjects without psoriasis. Stratified Cox proportional hazards models were used to compare the risks of CP between the patients with and without psoriasis.

Results
The incidence of CP was 0.61 per 1000 person-years in patients with psoriasis and 0.34 per 1000 person-years in controls during a mean 6.6-year follow-up period. Before adjustment, patients with psoriasis had a significantly higher risk of CP (crude hazard ratio (HR) = 1.81; 95% confidence interval (CI) = 1.53–2.15), and the risk remained significantly higher after adjustments for gender, age group, medications, and comorbidities (adjusted HR (aHR) = 1.76; 95% CI = 1.47–2.10). All psoriasis patient subgroups other than those with arthritis, including those with mild and severe psoriasis and those without arthritis, had significantly increased aHRs for CP, and the risk increased with increasing psoriasis severity. Psoriasis patients taking nonsteroidal anti-inflammatory drugs (aHR = 0.33; 95% CI = 0.22–0.49) and methotrexate (aHR = 0.28; 95% CI = 0.12–0.64) had a lower risk of developing CP after adjustments.
Conclusions
Psoriasis is associated with a significantly increased risk of CP. The results of our study call for more research to provide additional insight into the relationship between psoriasis and CP.

Introduction
Psoriasis, a chronic inflammatory T-cell-mediated disease, affects 2–3% of the general population and was considered a disease limited to the skin and joints. Recent research has emphasized that psoriasis is a multisystemic disease associated with a variety of comorbidities, such as cardiovascular disease, diabetes, and chronic renal diseases. However, only few small studies or case reports have been published regarding the pancreas dysfunction or acute pancreatitis in psoriasis. And the study investigating the risk of chronic pancreatitis (CP) in psoriasis is lacking.

CP, an irreversible inflammatory disease of the pancreas, is characterized by chronic inflammatory cell infiltration and acinar cell degeneration, leading to progressive destruction of exocrine and endocrine tissue and fibrosis. Moreover, patients with CP have a higher mortality and morbidity than the general population. Chronic pancreatitis may have an insidious onset or develop following episodes of acute pancreatitis. Emerging work had strongly suggested autoimmune diseases, including rheumatoid arthritis, Sjogren’s syndrome, and inflammatory bowel disease, are frequently associated with autoimmune pancreatitis. Acute pancreatitis has also been related to long-term use of immunosuppressives. Moreover, there is a shared common factor between CP and psoriasis, including hyperlipidemia, chronic renal failure, and cigarette smoke. Therefore, we assessed the risk of CP in a large nationally representative, population-based cohort of Chinese patients with psoriasis from Taiwan.

Materials and Methods
Study Design
The design of this study was a retrospectively cohort study. We took advantage of population-based claim data from National Health Insurance (NHI) to identify psoriasis patients during 2004–2006. We matched these patients with general non-psoriasis population during 2004–2006 by age and gender, and follow up their incidence of CP for at least five years. Cohort entry of patients with psoriasis was the date when psoriasis was first diagnosed; matched subjects without psoriasis were assigned the same entry date. This protocol was approved by the Investigational Research Bureau of National Taiwan University Hospital Hsin-Chu Branch (103-024-E).

Data sources
The Taiwan National Health Insurance Research Database (NHIRD) is an administrative database, compiled by the Taiwan National Health Research Institutes, which is widely used in academic studies. Because the Taiwan NHI program covers nearly 100% of approximately 23 million Taiwan residents, the NHIRD stores data from a very large number of individuals. This compulsory health insurance program provides comprehensive benefits, including ambulatory care and inpatient services. Therefore, NHIRD holds detailed information that includes...
registration files, demographic data, clinical visits and hospitalizations, diagnostic codes, prescription profiles, and procedures and surgeries. Patients' identities are encrypted to protect privacy. In order to ensure the accuracy and reliability of coding, the Bureau of the NHI of Taiwan performs random crosschecking and peer reviews, requires justification for any claim by another independent physician, and imposes heavy fines for false claims, overcharging, or malpractice for fraudulent claims. Thus, the NHIRD data are generally accepted as accurate and reliable.

This study used two sources in the NHIRD to identify patients with psoriasis and matched subjects: 1) a dataset that included claims from all patients with psoriasis in Taiwan from 2003 to 2011, and 2) the Longitudinal Health Insurance Database (LHID) 2000, a longitudinal database containing all healthcare information on a representative community-based Taiwan population from 2000 to 2011.

Study population

The cohort of patients with psoriasis included all individuals diagnosed with psoriasis (International Classification of Disease, Ninth Revision, Clinical Modification [ICD-9-CM] codes 696.0, 696.1, 696.8) between January 1, 2004, and December 31, 2006. For data accuracy, only individuals diagnosed twice with psoriasis by dermatologists during ambulatory visits or inpatient care were included. The date of the first psoriasis diagnosis was designated as the index date from which follow-up began. We further excluded subjects younger than 18 years, patients who had a history of chronic or acute pancreatitis (ICD-9-CM codes 577.0 and 577.1), or pancreatic cancer (ICD-9 code 157) before the index date.

We extracted the control subjects from the LHID2000. We first excluded every subject who had received a diagnosis of psoriasis in the LHID2000. For each psoriasis patient, four subjects without psoriasis, matched on age and gender, were randomly selected from the LHID2000. The index date for the control cohort was corresponding to that given by each matched case. We also ensured that subjects selected for the control cohort had never been given a diagnosis of pancreatitis or pancreatic cancer before their index date (Fig 1).

![Fig 1. Flowchart. Selection of the study population.](doi:10.1371/journal.pone.0160041.g001)
Psoriasis patients were classified into groups with severe and mild psoriasis. Criteria defining severe psoriasis were having received systemic antipsoriatic therapy and/or phototherapy at least once during the first 3 years of follow-up. Patients who had never received systemic antipsoriatic therapy and/or phototherapy were designated as having mild psoriasis. Patients were also classified into groups with psoriatic arthritis (PsA), which was defined as those with at least 2 claims using ICD-9-CM code 696.0 during the same period; otherwise, patients were considered to have psoriasis without PsA.

Outcomes

The primary outcome was defined as first ambulatory visit or hospitalizations for CP (ICD-9-CM code 577.1), no matter the patients were alive or passed away after the CP event. All subjects were followed up from the index date until the incidence of CP or censored at the end of study period or the date of disenrollment (which is due to death most of the time).

Statistical analysis

The main analysis assessed time to the first CP. Patients who did not have CP before death or the end of the study were censored. We used the chi-square test to examine associations between the two CP exposure groups (Y/N) for categorical variables. Stratified Cox proportional hazards models were used to estimate the risk of CP. The multivariate models included adjustments for the following: (1) model 1: demographic variables (age groups, gender), cardiovascular conditions, and medical history (cholelithiasis (ICD-9-CM 574), hypertension (ICD-9-CM 362.11, 401–405, and 437.2), hypertriglyceridemia (ICD-9-CM 272.1), diabetes (ICD-9-CM 250.xx), hepatitis B (ICD-9-CM 070.2, 070.3, and V02.61) and C (ICD-9-CM 070.41, 070.44, 070.51, 070.54, V02.62, and 070.7), cardiovascular disease (ICD-9-CM 410–429), obesity (ICD-9-CM 278.0x), alcohol-related illness (ICD-9-CM 291, 303, 305.0, 571.0, 571.1, 571.2, 571.3, 790.3, and V11.3), chronic obstructive pulmonary disease (ICD-9-CM 491, 492, and 496), and tobacco use disorder (ICD-9-CM 305.1)). (2) model 2: those variables mentioned above plus medications used (methotrexate, cyclosporine, azathioprine, hydroxyurea, cyclophosphamide, acitretin, NSAID, etanercept, and adalimumab). Moreover, because we did not want to lose observations of treated subjects and wanted an interpretable overall treatment effect, we further used propensity score weighting to re-analyze the results. Weighting would allow us to estimate both the average treatment effect of the entire population (ATE weighting) and that of the treated (ATT weighting).[26] The ATE is “the average effect of moving an entire population from untreated to treated.” For the ATE weighing, we applied stabilized ATE weighting because it can deal with the extreme values of propensity scores. The ATT is “the average effect of treatment on those subjects who ultimately received the treatment.”[26]

In subgroup analyses, each subgroup compared with their matched subjects, and risks analyzed as above. Multiple sensitivity analyses were performed to test the underlying assumptions of our primary analysis and the robustness of our findings. All p-values were two sided, with p<0.05 considered statistically significant. All statistical analyses were performed using SAS version 9.2.

Results

Table 1 shows the sociodemographic characteristics in subjects with and without psoriasis. Patients with psoriasis were more likely to have diabetes (10.92% vs. 7.48%, P < 0.001), hypertension (22.0% vs. 16.3%, P < 0.001), hypertriglyceridemia (0.99% vs. 0.68%, P < 0.001), cardiovascular disease (11.65% vs. 8.63%, P < 0.001), alcohol-related illness (1.55% vs. 0.92%, P < 0.001), obesity (0.37% vs. 0.20%, P < 0.001), chronic obstructive pulmonary disease
Table 1. Distribution of gender, age, comorbidity, medications in individuals with and without psoriasis.

| Characteristic                        | Subjects with psoriasis n = 48,430 (%) | Subjects without psoriasis n = 193,720 (%) | p-value |
|---------------------------------------|----------------------------------------|--------------------------------------------|---------|
| **Sex**                               |                                        |                                            |         |
| Female                                | 20,069 (41.44%)                        | 80,276 (41.44%)                           | 1.00    |
| Male                                  | 28,361 (58.56%)                        | 113,444 (58.56%)                         |         |
| **Age Group**                         |                                        |                                            |         |
| 18–29                                 | 10,367 (21.41%)                        | 41,468 (21.41%)                          | 1.00    |
| 30–39                                 | 8,222 (16.98%)                         | 32,888 (16.98%)                         |         |
| 40–49                                 | 9,283 (19.17%)                         | 37,132 (19.17%)                         |         |
| 50–59                                 | 7,966 (16.45%)                         | 31,864 (16.45%)                         |         |
| 60–69                                 | 5,481 (11.32%)                         | 21,924 (11.32%)                         |         |
| ≥70                                   | 7,111 (14.68%)                         | 28,444 (14.68%)                         |         |
| **Comorbidity**                       |                                        |                                            |         |
| Hypertension                          | 10,655 (22.00%)                        | 31,517 (16.27%)                         | <0.0001 |
| Diabetes                              | 5,287 (10.92%)                         | 14,491 (7.48%)                          | <0.0001 |
| Hypertriglyceridemia                  | 481 (0.99%)                            | 1,323 (0.68%)                           | <0.0001 |
| Obesity                               | 178 (0.37%)                            | 389 (0.20%)                             | <0.0001 |
| Cardiovascular disease                | 5,644 (11.65%)                         | 16,716 (8.63%)                         | <0.0001 |
| Alcoholrelated illness                | 752 (1.55%)                            | 1,788 (0.92%)                           | <0.0001 |
| Cholelithiasis                        | 609 (1.26%)                            | 1,918 (0.99%)                           | <0.0001 |
| Chronic obstructive pulmonary disease | 3,256 (6.72%)                          | 8,946 (4.62%)                           | <0.0001 |
| Hepatitis B                           | 101 (0.21%)                            | 361 (0.19%)                             | 0.32    |
| Hepatitis C                           | 456 (0.94%)                            | 1,102 (0.57%)                           | <0.0001 |
| Tobacco use disorder                  | 259 (0.53%)                            | 674 (0.35%)                             | <0.0001 |
| Chronic kidney disease                | 2,164 (4.47%)                          | 6,214 (3.21%)                           | <0.0001 |
| **Drug**                              |                                        |                                            |         |
| Methotrexate                          | 4,950 (10.22%)                         | 865 (0.45%)                             | <0.0001 |
| Cyclosporine                          | 711 (1.47%)                            | 191 (0.10%)                             | <0.0001 |
| Azathioprine                          | 370 (0.76%)                            | 255 (0.13%)                             | <0.0001 |
| Hydroxyurea                           | 69 (0.14%)                             | 105 (0.05%)                             | <0.0001 |
| Cyclophosphamide                      | 179 (0.37%)                            | 465 (0.24%)                             | <0.0001 |
| Acitretin                             | 2,474 (5.11%)                          | 82 (0.04%)                              | <0.0001 |
| NSAID                                 | 46,040 (95.07%)                        | 165,263 (85.31%)                        | <0.0001 |
| Etanercept                            | 137 (0.28%)                            | 57 (0.03%)                              | <0.0001 |
| Adalimumab                            | 97 (0.2%)                              | 32 (0.02%)                              | <0.0001 |

(6.72% vs. 4.62%, P < 0.001), hepatitis C (0.94% vs. 0.57%, P < 0.001), and cholelithiasis (1.26% vs. 0.99%, P < 0.001) than people without psoriasis at the baseline (Table 1).

The incidence of CP during a mean 6.6-year follow-up period was 0.61 per 1000 person-years in patients with psoriasis and 0.34 per 1000 person-years in controls. Before adjustment, patients with psoriasis had a significantly higher risk of CP (crude HR 1.81; 95% CI 1.53–2.15), which remained significant after adjustment (adjusted HR [aHR] 1.76; 95% CI 1.47–2.10) (Table 2). We further grouped patients with psoriasis into those with mild or severe psoriasis and those with or without PsA. All psoriasis patient subgroups, including those with mild (aHR 1.81; 95% CI 1.50–2.19) and severe (aHR 1.68; 95% CI 1.02–2.78) psoriasis and those without arthritis (aHR 1.94; 95% CI 1.60–2.37), had significantly increased aHRs for CP, except those with arthritis (aHR 1.20; 95% CI 0.81–1.79). (Table 2).
Table 2. Incidence of and hazard ratios (HRs) for chronic pancreatitis in subjects with psoriasis (patients) and without psoriasis (controls).

| Variable                  | Control (n = 193,720) | Patients (n = 48,430) | Control (n = 60,316) | Patients (n = 15,079) | Control (n = 133,404) | Patients (n = 33,351) | Control (n = 151,972) | Patients (n = 37,993) | Control (n = 41,748) | Patients (n = 10,437) |
|---------------------------|-----------------------|-----------------------|----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| Follow-up time (years)    | Mean(SD)              | Median(Q1,Q3)         | No of person years   | No(%) of new cases of chronic pancreatitis | Incidence per 1000 person years(95% CI) | Hazard ratio (95% CI) for incident CP |
|                           | 6.59(0.89)            | 6.66 (1.54)           | 1,276,332            | 433(0.22%)            | 0.34(0.31–0.37)       | 1.81(1.53–2.15)^‡   |
|                           | 6.58 (0.91)           | 6.66 (1.54)           | 318,729              | 196 (0.40%)           | 0.61 (0.53–0.71)      | 1.64 (1.39–1.95)^‡   |
|                           | 6.58 (0.88)           | 6.62 (1.53)           | 396,753              | 119 (0.20%)           | 0.30 (0.25–0.36)      | 1.04 (0.72–1.52)     |
|                           | 6.58 (0.89)           | 6.62 (1.53)           | 99,155               | 36 (0.24%)            | 0.36 (0.26–0.50)      | 1.87 (1.55–2.27)^‡   |
|                           | 6.58 (0.92)           | 6.67 (1.54)           | 879,580              | 314 (0.24%)           | 0.36 (0.32–0.40)      | 1.77 (1.46–2.13)^‡   |
|                           | 6.56 (0.89)           | 6.67 (1.55)           | 219,573              | 160 (0.48%)           | 0.73 (0.62–0.85)      | 1.77 (1.46–2.13)^‡   |
|                           | 6.55 (0.91)           | 6.62 (1.53)           | 997,367              | 338 (0.22%)           | 0.34 (0.30–0.38)      | 1.81 (1.50–2.19)^‡   |
|                           | 6.68 (0.89)           | 6.62 (1.53)           | 249,013              | 164 (0.43%)           | 0.66 (0.57–0.77)      | 1.68 (1.02–2.78)^†   |
|                           | 6.68 (0.90)           | 6.78 (1.55)           | 278,965              | 95 (0.23%)            | 0.34 (0.28–0.42)      | 1.35 (0.90–2.01)     |
|                           |                       | 69,716                |                      |                       | 0.46 (0.32–0.65)      |                      |

Abbreviations: CI, confidence interval; CP, chronic pancreatitis; HR, hazard ratio; IQR, interquartile range; SD, standard deviation.

*‡p < 0.05 for comparison between patients with psoriasis and non-psoriasis.

*Model 1 is adjusted for gender, age group, and all comorbidities listed.

*Model 2 is adjusted for gender, age group, medications, and all comorbidities listed.

doi:10.1371/journal.pone.0160041.t002
Next, we investigated the association between concomitant drug and the risk of developing CP (Table 3). Our data analysis compared psoriasis patients who had used and those who had not used a specific anti-psoriatic drug. Exposure to non-steroidal anti-inflammatory drugs (NSAIDs) (aHR 0.33; 95% CI 0.22–0.49) and methotrexate (aHR 0.28; 95% CI 0.12–0.64) therapy were associated with a decreased risk of CP after adjustment for age, gender, comorbidities, and other medications. Cyclosporine, azathioprine, cyclophosphamide, acitretin, and hydroxyurea use didn’t show a significant association with the risk of CP.

To further verify the robustness of the primary results, we performed sensitivity analysis (Table 4). Primary model with propensity score weighting was used to control for selection bias between psoriasis and comparison groups. The results were similar to the primary analyses. Moreover, patients with severe psoriasis had a higher aHR for CP than those with mild

Table 3. Risks of chronic pancreatitis among psoriasis patients treated with medications.

| Medication     | Crude HR (95%CI) | Adjusted HR (95%CI) |
|----------------|------------------|---------------------|
| Methotrexate   | 0.27 (0.12–0.62) | 0.28 (0.12–0.64)    |
| Cyclosporine   | 0.68 (0.17–2.74) | 1.31 (0.30–5.73)    |
| Azathioprine   | 1.33 (0.33–5.36) | 2.20 (0.53–9.21)    |
| Hydroxyurea    | 3.59 (0.50–25.64)| 4.32 (0.60–31.12)   |
| Cyclophosphamide | 1.35 (0.19–9.65)| 1.76 (0.23–13.21)   |
| Acitretin      | 0.77 (0.38–1.58) | 0.88 (0.43–1.82)    |
| NSAID          | 0.30 (0.20–0.45) | 0.33 (0.22–0.49)    |

Abbreviations: CI, confidence interval; HR, hazard ratio; NSAIDs, nonsteroidal anti-inflammatory drugs.
†p < 0.05
‡p < 0.001 for comparison between patients with psoriasis and non-psoriasis.
*Adjusted for gender, age, other medications, and all comorbidities listed.

Table 4. Sensitivity analyses of the risk of chronic pancreatitis in psoriasis compared with the reference control cohort.

|                     | Crude HR (95% CI) | aHR (95% CI)* |
|---------------------|------------------|---------------|
| Primary model       | 1.81 (1.53–2.15) | 1.76 (1.47–2.10) |
| Primary model with exclusion of alcohol related illness | 1.72 (1.44–2.06) | 1.73 (1.44–2.09) |
| Propensity score weighting model (ATE) | 1.67 (1.41–1.98) | 1.89 (1.61–2.22) |
| Propensity score weighting model (ATE) with exclusion of alcohol related illness | 2.03 (1.72–2.41) | 1.91 (1.61–2.25) |
| Primary model with modified definition of the outcomeb | 2.08 (1.73–2.50) | 2.03 (1.67–2.45) |

Abbreviations: aHR, adjusted hazard ratio; ATE: average treatment effect; HR: hazard ratio; CI: confidence interval
†p < 0.01 for comparison between patients with psoriasis and non-psoriasis.
*Adjusted for gender, age group, medications, and all comorbidities listed.
‡ Refers to having ICD-9-CM code of chronic pancreatitis plus at least one of the following: undergoing amylase/lipase exams within 6 months prior to the diagnosis of chronic pancreatitis or receiving medical imaging studies such as abdominal ultrasonography, computed tomography, or magnetic resonance imaging within 6 months before and after the diagnosis of chronic pancreatitis.

doi:10.1371/journal.pone.0160041.t003
doi:10.1371/journal.pone.0160041.t004
psoriasis (aHR 2.37 vs. 2.06) (Table A in S1 File). To estimate the impact of alcohol consumption on the risk of CP in patients with psoriasis, we excluded patients with alcohol related illness prior to study start, which did not attenuate the observed association between psoriasis and risk of CP. We also used a more specific outcome definition of CP by combining the ICD-9-CM diagnostic code with imaging studies, such as abdominal ultrasonography, computed tomography, or magnetic resonance imaging. Similar results were also apparent for the risk of CP in psoriasis.

Discussion

CP is meant to be an irreversible process of damage to the pancreatic tissue and thus eventually causes a variety of morbidity, including debilitating pain, progression to diabetes, and pancreatic cancer.[16] Moreover, patients with CP had a 4-fold higher mortality than the general population.[15] A recent observational study using the UK General Practice Research Database showed that psoriasis patients have an increased risk of pancreatic cancer (Incidence rate ratios 2.20; 95%CI 1.18–4.09) and the risk increased with duration of psoriasis.[27] Although the actual mechanisms contributing to the association between CP and psoriasis remains to be elucidated, the role of the immune system and inflammatory process might be the pathogenic link between the two conditions. In both mouse and human studies, inflammation has been shown to be a precursor to CP.[28–29] The pivotal mediators of inflammation in psoriasis, including tumor necrosis factor (TNF) -α, interleukin (IL)-1, IL-17, and IL-18, are also overexpressed in patients with pancreatitis and their expressions are related to the severity of pancreatic destruction and eventual mortality.[28, 30–33] Mews et al. showed that persistent activation of the stellate pancreatic cells by TNF-α and IL-1 could be a factor in the progression of CP.[34–35] In murine models, TNF-α has been shown to induce severe pancreatitis and be involved in subsequent pancreatic fibrosis by inducing TGF-β.[29] Moreover, previous studies have pinpointed that TNF-α308G/A polymorphism, a genetic predisposition to influence TNF levels, is significantly associated with the risk of developing both psoriasis and CP.[34, 36] Accordingly, CP, like psoriasis, is also an immune-mediated disease, at least in part. Prior research has also shown that aberrant autoimmunity in patients with immunodeficiency disorders may predispose them to having gastrointestinal or pancreatic disorders and skin diseases, including psoriasis.[37–40] Thus, deficiencies in immunohomeostasis might be the link between psoriasis and chronic pancreatitis. Our data showed that the incidence and HR of CP were greater in patients with psoriasis than control subjects after adjusting for potential confounding factors. Moreover, the risk for CP increased in parallel with the severity of psoriasis (ATE propensity score-weighted model). The finding was in agreement with the aforementioned studies and suggested that the involvement of other factors intrinsically linked to psoriasis, such as dysregulation of the immune system, predisposed patients with psoriasis to the development of CP.

Further evaluation regarding the effect of antipsoriatic drugs on the new onset of CP in patients with psoriasis showed that exposure to NSAIDs and methotrexate were associated with a reduced HR than non-exposure. This result was consistent with previous studies. [41–42] Prior research had suggested that administration of NSAIDs may significantly reduce the risk of acute pancreatitis after retrograde endoscopic cholangiopancreatography, which was proposed to be caused by activation of chemokines after endoscopic maneuvers.[41–42] A recent study also showed that methotrexate may reduce inflammation-related cytokine levels in acute pancreatitis[43] and relieve disease progression. Moreover, methotrexate had been used as an alternative treatment in azathioprine and 6-mercaptopurine induced pancreatitis in patients with inflammatory bowel disease.[43] Cyclosporine, azathioprine, cyclophosphamide, and hydroxyurea have been reported to induce and exacerbate acute pancreatitis.[44–48]
Consistent with these studies, our study found that psoriasis patients taking cyclosporine, azathioprine, cyclophosphamide, and hydroxyurea had an increased risk of CP, though the associations were not statistically significant, probably due to small number of patients who exposed to these drugs.

Acitretin therapy may cause changes in the serum lipid profile resulting in hyperlipidemia in some patients.[49–50] In clinical trials, with doses ranging from 10 to 75 mg/day of acitretin, elevation of triglyceride levels (defined as \(>20 \text{ mg/dL}\)) were noted in 66% of patients.[50] However, only one case treated with acitretin of fatal fulminant pancreatitis has been reported.[50] In agreement with previous reports, our results showed that acitretin use was not associated with significantly increased risk of CP. A possible explanation is increases of serum triglycerides to levels associated with pancreatitis are not common during acitretin therapy.

We also investigated the risk conferred by psoriasis in different patient subgroups. The HRs for CP were significantly increased in all subgroups, including those with mild and severe psoriasis and those with and without PsA. However, the risks for CP in patients with PsA were not significantly higher than those without PsA. The results may be attributed to multiple factors. The more frequent use of NSAIDs for pain associated with arthritis in patients with PsA might at least partially reduce the risk of CP compared with that for patients without PsA. This was probably due to the fact that when the risk was already elevated, mainly owing to psoriasis, the presence of concomitant arthritis did not have any additional effect. It is also possible that patients with PsA might have higher frequencies of comorbidities in these subgroups, which attenuated the additional effects conferred by arthritis on the risks for CP.

Several important limitations of our study should be considered. First, the diagnoses of CP and psoriasis used in our study relied on administrative claims data. Patients may be underdiagnosed or overdiagnosed with CP, resulting in misclassification bias. However, nondifferential misclassification bias would bias the results toward the null. Moreover, as mentioned above, an internal validation system exists for the accuracy of each claim included in the NHIRD. Previous reports have also confirmed the reliability of the diagnosis accuracy of psoriasis and pancreatitis based on ICD-9 codes.[6, 18, 51] A recent study by Shen et al. also validated the diagnostic code of acute pancreatitis, showing a positive predictive value of 90.0% (95% CI, 79.2–96.2%).[52] To further validate the results, we used a more rigorously defined outcome (e.g., CP with compatible orders of preceding imaging or laboratory examinations) in the sensitivity analysis and found results similar to those of the primary analyses (Table B in S1 File). Second, the NHIRD does not provide some covariables such as behavior risk factors (the amount of daily alcohol consumption and tobacco use) due to the inherent limitation of the database. However, some of these unmeasured confounders may have been controlled by including alcohol dependence, tobacco use disorder, chronic obstructive pulmonary disease, and other comorbidities as an alternative covariable in the analyses. Third, we relied on treatment with systemic therapies or phototherapy as a surrogate marker for severe disease. However, it is possible that physicians are less likely to give systemic medications to patients with severe psoriasis with coexisting medical illnesses out of concern for systemic adverse effects. It is likely that there is misclassification with regard to psoriasis severity as with all epidemiologic studies. However, the reliability and validity of using these methods for grouping severe psoriasis has been demonstrated in previous studies.[8, 53–56] Lastly, more frequent hospital visits by patients with psoriasis than the general population may result in potential surveillance bias as they would have easier access to examinations, which might overestimate the risk of CP related to psoriasis. However, laboratory examinations (amylase/lipase) or imaging modalities for CP, were not a routine procedure performed during the therapeutic monitoring of psoriasis.
In conclusion, our nationwide study demonstrated that patients with psoriasis are at a significantly elevated risk of CP and the risk increased with severity of psoriasis. CP was thought to have a complex aetiology and the increased development of CP in patients with psoriasis was multifaceted and may be the result of several ongoing processes, including chronic inflammation in psoriasis, drugs, autoimmune pancreatitis, and genetic and behavioral risk factors. These results suggest the need for physicians to be aware of the pancreatic comorbidity associated with psoriasis and that earlier detection and intervention may reduce the significant morbidity and mortality in CP. Future studies are needed to better explore the pathophysiological basis underlying the relationship between psoriasis and CP, and to investigate the efficacy of systemic anti-inflammatory therapy in decreasing the risk of CP in patients with psoriasis.

Supporting Information

S1 File. Table A. Hazard ratios for chronic pancreatitis in patients with and without (controls) psoriasis derived from different Cox proportional hazard models. Table B. Sensitivity analyses. (DOCX)

Acknowledgments

This study is based in part on data from the National Health Insurance Research Database provided by the National Health Insurance Administration, Ministry of Health and Welfare and managed by the National Health Research Institutes. The interpretation and conclusions contained herein do not represent those of the Taiwan National Health Insurance Administration, Ministry of Health and Welfare or National Health Research Institutes. There is no prior presentation except submitted as a poster in 21st ISPOR (International Society for Pharmacoeconomics and Outcomes Research) Annual International Meeting, May 21–25, 2016.

Author Contributions

Conceived and designed the experiments: HYC CFH YTC WFH TFT. Performed the experiments: HYC CFH YTC WFH TFT. Analyzed the data: HYC CFH YTC. Contributed reagents/materials/analysis tools: HYC CFH YTC WFH TFT. Wrote the paper: HYC CFH YTC WFH TFT.

References

1. Nestle FO, Kaplan DH, Barker J. (2009) Psoriasis. N Engl J Med 361:496–509. [pii] doi: 10.1056/NEJMra0804595 PMID: 19641206.
2. Chiu H-Y, Cheng Y-P, Tsai T-F. (2012) T helper type 17 in psoriasis: From basic immunology to clinical practice. Dermatologica Sinica 30:136–141. doi: 10.1016/j.dsi.2012.08.002
3. Wang T-C, Chiu H-Y, Wang T-S, Tsai T-F. (2015) Practical experience of ustekinumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to previous tumor necrosis factor blockers. Dermatologica Sinica 33:5–10. doi: 10.1016/j.dsi.2014.09.005
4. Yang H-J, Yang K-C. (2015) Impact of psoriasis on quality of life in Taiwan. Dermatologica Sinica 33:146–150. doi: 10.1016/j.dsi.2015.02.001
5. Mehta NN, Yu Y, Pinnelas R, Krishnamoorthy P, Shin DB, Troxel AB, et al. (2011) Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 124:775 e1-e6. doi: S0002-9343(11)00327-5 [pii] doi:10.1016/j.amjmed.2011.03.028 PMID: 21787906.
6. Chiu HY, Chang WL, Huang WF, Wen YY, Tsai YW, Tsai TF. (2015) Increased risk of arrhythmia in patients with psoriatic disease: A nationwide population-based matched cohort study. J Am Acad Dermatol 73:429–438. doi: S0190-9622(15)01768-5 [pii] doi: 10.1016/j.jaad.2015.06.023 PMID: 26186627.
7. Armstrong AW, Harskamp CT, Armstrong EJ. (2013) Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol 149:84–91. doi: 10.1001/jama dermatol.149.8.840 PMID: 23407990.

8. Chiu HY, Huang HL, Li CH, Yin YJ, Chen HA, Hsu ST, et al. (2015) Increased risk of glomerulonephritis and chronic kidney disease in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study. Br J Dermatol 173:146–154. doi: 10.1111/bjd.13599 PMID: 25511692.

9. Azfar RS, Seminara NM, Shin DB, Troxel AB, Margolis DJ, Gelfand JM. (2012) Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis. Arch Dermatol 148:995–1000. doi: 10.1001/archdermatol.2012.1401 PMID: 22710320.

10. Gelfand JM, Neumann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735–1741. doi: 10.1001/jama.296.14.1735 PMID: 17032986.

11. Amouzougan A, Chopin F, Patouillard B, Pallot-Prades B, Le Gars L, Thomas T. (2007) Recurrent acute pancreatitis in psoriatic arthritis. Joint Bone Spine 74:513–515. doi: S1297-319X(07)00175-3 [pii] doi: 10.1016/j.jbspin.2007.01.022 PMID: 17644458.

12. Farber EM, Johnsen RE, Shwachman H. (1957) The exocrine function of the pancreas in psoriasis. AMA Arch Derm 76:236–238. PMID: 13443513.

13. Clayton H, Flatz L, Vollenweider-Roten S, Schoeper A, Gilliet M, Conrad C. (2013) Anti-TNF therapy in patients with acute on chronic pancreatitis. Gut 54:703–709. doi: S0015-5873(03)15647-0 [pii] doi: 10.1136/gut.2004.047142 PMID: 15831920.

14. Okazaki K, Uchida K, Ohana M, Nakase H, Uose S, Inai M, et al. (2000) Autoimmune-related pancreatitis. Gut 47:1184–1189. doi: S0015-5120(99)32930-3 [pii] doi: 10.1016/S0015-5120(99)32930-3 PMID: 11126315.

15. Nojgaard C. (2010) Prognosis of acute and chronic pancreatitis in the rat. Am J Pathol 166:729–736. doi: S0002-9440(10)62294-8 PMID: 20770186.

16. Nair RJ, Lawler L, Miller MR. (2007) Chronic pancreatitis. Am Fam Physician. 76:1679–1688. PMID: 18092710.

17. Okazaki K, Uchida K, Ohana M, Nakase H, Uose S, Inai M, et al. (2000) Autoimmune-related pancreatitis is associated with autoantibodies and a Th1/Th2-type cellular immune response. Gastroenterology 118:573–581. doi: S0016-5085(00)80177-0 [pii] PMID: 10702209.

18. Chang CC, Chiu CS, Lin HL, Wang LH, Chang YS, Lin HC. (2015) Increased Risk of Acute Pancreatitis in Patients with Rheumatoid Arthritis: A Population-Based Cohort Study. PLoS One 10:e0135187. doi: 10.1371/journal.pone.0135187 PMID: 26262880.

19. Aparisi L, Farre A, Gomez-Cambronero L, Martinez J, De Las Heras G, Corts J, et al. (2005) Antibodies to carbonic anhydrase and IgG4 levels in idiopathic chronic pancreatitis: relevance for diagnosis of autoimmune pancreatitis. Gut 54:703-709. doi: 10.1136/gut.2004.047142 PMID: 15831920.

20. Uchida K, Okazaki K, Nishi T, Uose S, Nakase H, Ohana M, et al. (2002) Experimental immune-mediated pancreatitis in neonatally thymectomized mice immunized with carbonic anhydrase II and lactoferrin. Lab Invest 82:411–424. PMID: 11950899.

21. Davidsson TS, Longnecker DS, Hickey WF. (2005) An experimental model of autoimmune pancreatitis in the rat. Am J Pathol 166:729–736. doi: S0002-9440(10)62294-8 PMID: 15743785.

22. Eisemann AD, Becker NJ, Miner PB Jr., Fleming J. (1989) Pancreatitis and gold treatment of rheumatoid arthritis. Ann Intern Med 111:860–861. PMID: 2573305.

23. Kolk A, Horneff G, Wilgenbus KK, Wahn V, Gerharz CD. (1995) Acute lethal necrotising pancreatitis in childhood systemic lupus erythematosus—possible toxicity of immunosuppressive therapy. Clin Exp Rheumatol 13:399–403. PMID: 7554572.

24. Hamed I, Lindeman RD, Czerwinski AW. (1978) Case report: acute pancreatitis following corticosteroid and azathioprine therapy. Am J Med Sci 276:211–219. PMID: 736057.

25. Patoyan D, Levin B, Simonowitz D. (1977) Azathioprine-associated acute pancreatitis. Am J Dig Dis 22:839–840. PMID: 900102.

26. Kurth T, Walker AM, Glynn RJ, Chan KA, Gaziano JM, Berger K, et al. (2006) Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 163:262–270. PMID: 16371515.

27. Brauchl YB, Jick SS, Miret M, Meier CR. (2009) Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis. J Investig Dermatol 129:2604–2612. doi: 10.1038/jid.2009.113 PMID: 19440219.

28. Manjari KS, Jyothy A, Vidyasagar A, Prabhakar B, Nallari P, Venkateshwarlu A. (2013) Matrix metalloproteinase-9, transforming growth factor-beta1, and tumor necrosis factor-alpha plasma levels in...
chronic pancreatitis. Indian J Gastroenterol 32:103–107. doi: 10.1007/s12664-012-0299-5 PMID: 23408257.

29. Xie MJ, Motoo Y, Su SB, Sawabu N (2001). Expression of tumor necrosis factor-alpha, interleukin-6, and interferon-gamma in spontaneous chronic pancreatitis in the WBN/Kob rat. Pancreas 22:400–408. PMID: 11345142.

30. Pietrzak A, Jastrzebska I, Chodorowska G, Maciejewski R, Dybiec E, Juszkiewicz-Borowiec M, et al. (2009) Psoriasis vulgaris and digestive system disorders: is there a linkage? Folia Histochem Cytobiol 47:517–524. [pii] doi:10.2478/s10042-009-0107-y PMID: 20164041.

31. Yuan BS, Zhu RM, Braddock M, Zhang KH, Shi W, Zheng MH. (2007) Interleukin-18: a pro-inflammatory cytokine that plays an important role in acute pancreatitis. Expert Opin Ther Targets 11:1261–1171. doi: 10.1517/14728222.11.10.1261 PMID: 17907957.

32. Ni J, Hu G, Xiong J, Shen J, Yang L, Tang M, et al. (2013) Involvement of interleukin-17A in pancreatic damage in rat experimental acute necrotizing pancreatitis. Inflammation 36:53–65. doi: 10.1007/s10753-012-9519-5 PMID: 22990529.

33. Guzel S, Erfan G, Kulac M, Guzel EC, Kucukyalcin V, Kaya S, et al. (2015) Chemerin and calprotectin levels correlate with disease activity and inflammation markers in psoriasis vulgaris. Dermatologica Sinica 33:1–4. doi: 10.1016/j.dsi.2014.08.003

34. Li C, Wang G, Gao Y, Liu L, Gao T. (2007) TNF-alpha gene promoter -238G>A and -308G>A polymorphisms alter risk of psoriasis vulgaris: a meta-analysis. J Invest Dermatol 127:1886–1892. doi: 10.1097/sj.jid.0000430029.00949.6f PMID: 17446901.

35. Uzzan M, Ko HM, Mehandru S, Cunningham-Rundles C. (2016) Gastrointestinal Disorders Associated with Common Variable Immune Deficiency (CVID) and Chronic Granulomatous Disease (CGD). Curr Gastroenterol Rep 18:17. doi:10.1007/s11894-016-0491-3 [pii]. PMID:26951230.

36. Kahn E, Anderson VM, Greco MA, Magid M. (1995) Pancreatic disorders in pediatric acquired immune deficiency syndrome. Hum Pathol 26:765–770. PMID:7628849.

37. Gualdi G, Lougaris V, Baronio M, Vitali M, Tampella G, Moratto D, et al. (2015) Burden of Skin Disease in Selective IgA Deficiency and Common Variable Immunodeficiency. J Investig Allergol Clin Immunol 25:369–371. PMID:26727769.

38. Pezzilli R, Morselli-Labate AM, Corinaldesi R. (2010) NSAIDs and Acute Pancreatitis: A Systematic Review. Pharmaceuticals 3:558. doi: 10.3390/ph3030558

39. Yoshihara T, Horimoto M, Kitamura T, Osugi N, Ikehara T, Kotani K, et al. (2015) 25 mg versus 50 mg dose of rectal diclofenac for prevention of post-ERCP pancreatitis in Japanese patients: a retrospective study. BMJ Open. 5:e006950. [pii] doi:10.1136/bmjopen-2014-006950 PMID: 25795692.

40. Duan L, Ma Y, Chi J, Wang X, Wesley AJ, Chen X. (2014) The regulatory role of immunosuppressants on immune abnormalities in acute pancreatitis. Biomed Rep. 2:193–198. doi: 10.3892/br.2013.208 [pii]. PMID:24649095.

41. Guo R, Du X, Weng JY, Deng CX, Wu SJ, Luo CW. (2009) [Acute pancreatitis induced by cyclosporine a following allogeneic hematopoietic stem cell transplant]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 17:472–475. doi: 10.3390/ph3030558

42. Hackert T, Pfeil D, Hartwig W, Fritz S, Gebhard MM, Klar E, et al. (2006) Ciclosporin aggravates tissue damage in ischemia reperfusion-induced acute pancreatitis. Pancreas 32:145–151. doi: 10.1097/01.mpa.0000194610.62723.1800006676-200603000-00004 [pii]. PMID:16552333.

43. Weersma RK, Peters FT, Oostenbrug LE, van den Berg AP, van Haastert M, Ploeg RJ, et al. (2004) Increased incidence of azathioprine-induced pancreatitis in Crohn’s disease compared with other diseases. Aliment Pharmacol Ther 20:843–850. [pii] doi:10.1111/j.1365-2036.2004.02197.x PMID:15479335.

44. Puckett JB, Butler WM, McFarland JA. (1982) Pancreatitis and cancer chemotherapy. Ann Intern Med 97:453. PMID:6896801.
48. Longhurst HJ, Pinching AJ.(2001) Drug Points: pancreatitis associated with hydroxyurea in combination with didanosine. BMJ 322:81. PMID: 11154621.

49. Ormerod AD, Campalani E, Goodfield MJ. (2010) British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol 162:952–963. [pii] doi: 10.1111/j.1365-2133.2010.09755.x PMID: 20423353.

50. Katz HI, Waalen J, Leach EE.(1999) Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol 41:S7–S12. doi: S0190-9622(99)70359-2 [pii]. PMID: 10459140.

51. Lai SW, Lin CL, Liao KF. (2015) Actively using clopidogrel correlates with an increased risk of acute pancreatitis in Taiwan. Int J Cardiol 183:263–266. doi: S0167-5273(14)01744-6 [pii] doi:10.1016/j.ijcard.2014.09.042 PMID: 25722184.

52. Shen HN, Lu CL, Li CY. (2012) Epidemiology of first-attack acute pancreatitis in Taiwan from 2000 through 2009: a nationwide population-based study. Pancreas 41:696–702. doi: 10.1097/MPA.0b013e31823db94100006676-201207000-00006 [pii]. PMID: 22699142.

53. Asgari MM, Wu JJ, Gelfand JM, Salman C, Curtis JR, Harrold LR, et al. (2013) Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996–2009. Pharmacoepidemiol Drug Saf 22:842–849. doi: 10.1002/pds.3447 PMID: 23637091.

54. Chiu HY, Huang HL, Li CH, Chen HA, Yeh CL, Chiu SH, et al.(2015) Increased Risk of Chronic Kidney Disease in Rheumatoid Arthritis Associated with Cardiovascular Complications—A National Population-Based Cohort Study. PLoS One 10:e0136508. doi: 10.1371/journal.pone.0136508 PONE-D-15-23571 [pii]. PMID: 26406879.

55. Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, et al. (2013) Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol 149:1173–1179. [pii] doi: 10.1001/jamadermatol.2013.5015 PMID: 23925466.

56. Lofvendahl S, Theander E, Svensson A, Carlsson KS, Englund M, Petersson IF. (2014) Validity of diagnostic codes and prevalence of physician-diagnosed psoriasis and psoriatic arthritis in southern Sweden—a population-based register study. PLoS One 9:e98024. doi: 10.1371/journal.pone.0098024 PONE-D-14-00131 [pii]. PMID: 24875275.